Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Growth 2023-2029

Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Growth 2023-2029

The global Group A and Group C Meningococcal Polysaccharide Vaccine market size is projected to grow from US$ 278.8 million in 2022 to US$ 422 million in 2029; it is expected to grow at a CAGR of 6.1% from 2023 to 2029.

Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.

After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.

LPI (LP Information)' newest research report, the “Group A and Group C Meningococcal Polysaccharide Vaccine Industry Forecast” looks at past sales and reviews total world Group A and Group C Meningococcal Polysaccharide Vaccine sales in 2022, providing a comprehensive analysis by region and market sector of projected Group A and Group C Meningococcal Polysaccharide Vaccine sales for 2023 through 2029. With Group A and Group C Meningococcal Polysaccharide Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Group A and Group C Meningococcal Polysaccharide Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Group A and Group C Meningococcal Polysaccharide Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Group A and Group C Meningococcal Polysaccharide Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Group A and Group C Meningococcal Polysaccharide Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Group A and Group C Meningococcal Polysaccharide Vaccine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Group A and Group C Meningococcal Polysaccharide Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Group A and Group C Meningococcal Polysaccharide Vaccine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Class 1 Vaccine
Class II Vaccine

Segmentation by application
Hospital
Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio

Key Questions Addressed in this Report

What is the 10-year outlook for the global Group A and Group C Meningococcal Polysaccharide Vaccine market?

What factors are driving Group A and Group C Meningococcal Polysaccharide Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Group A and Group C Meningococcal Polysaccharide Vaccine market opportunities vary by end market size?

How does Group A and Group C Meningococcal Polysaccharide Vaccine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.